AU
UK
CA
NZ
IND
US
Last update at 2026-06-03T20:01:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Bicycle Therapeutics price target lowered to $15 from $40 at Barclays
Fri 02 May 25, 06:01 PM| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -254.32093M | -173.79600M | -179.20700M | -114.24100M | -68.48200M |
| Minority interest | - | - | - | - | - |
| Net income | -218.96000M | -169.03100M | -180.66400M | -112.71700M | -66.81900M |
| Selling general administrative | 79.37M | 71.46M | 59.83M | 49.51M | 32.44M |
| Selling and marketing expenses | - | 0.72M | - | - | - |
| Gross profit | 72.59M | -137.69100M | -129.52000M | 14.46M | 11.70M |
| Reconciled depreciation | 6.42M | 7.17M | 6.55M | 3.69M | 1.41M |
| Ebit | -283.29849M | -172.06902M | -189.94600M | -116.65300M | -65.61800M |
| Ebitda | -276.86148M | -164.89200M | -183.40000M | -110.89700M | -65.49800M |
| Depreciation and amortization | 6.44M | 7.18M | 6.55M | 5.76M | 0.12M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -247.06500M | -209.87200M | -189.94600M | -116.65300M | -65.61800M |
| Other operating expenses | 356.05M | 245.15M | 216.92M | 131.12M | 77.31M |
| Interest expense | 0.21M | 1.73M | 3.26M | 3.34M | 2.98M |
| Tax provision | 0.15M | -4.76500M | 1.46M | -1.52400M | -1.66300M |
| Interest income | 28.46M | 34.28M | 14.00M | 5.76M | 0.12M |
| Net interest income | 28.26M | 32.55M | 10.74M | 2.41M | -2.86400M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.15M | -4.76500M | 1.46M | -1.52400M | -1.66300M |
| Total revenue | 72.59M | 35.27M | 26.98M | 14.46M | 11.70M |
| Total operating expenses | 349.62M | 72.18M | 60.43M | 131.12M | 77.31M |
| Cost of revenue | 6.44M | 172.97M | 156.50M | - | - |
| Total other income expense net | 28.98M | 36.08M | 10.74M | 2.41M | -2.86400M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -218.96000M | -169.03100M | -180.66400M | -112.71700M | -66.81900M |
| Net income applicable to common shares | - | - | - | -112.71700M | -66.81900M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 717.60M | 956.87M | 595.34M | 410.61M | 479.79M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | -35.59400M | 13.43M | 11.41M | 9.02M | 7.96M |
| Total liab | 107.62M | 163.81M | 224.41M | 139.83M | 133.54M |
| Total stockholder equity | 609.98M | 793.06M | 370.93M | 270.78M | 346.25M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 44.56M | 35.74M | 26.63M | 23.33M | 11.86M |
| Common stock | 0.89M | 0.89M | 0.55M | 0.39M | 0.38M |
| Capital stock | 0.89M | 0.89M | 0.55M | 0.39M | 0.38M |
| Retained earnings | -899.75100M | -680.79100M | -511.76000M | -331.09600M | -218.37900M |
| Other liab | - | - | - | 45.28M | 55.35M |
| Good will | - | - | - | - | - |
| Other assets | - | - | - | 8.46M | 3.45M |
| Cash | 628.11M | 879.52M | 526.42M | 339.15M | 438.68M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 56.98M | 67.23M | 69.54M | 53.34M | 36.24M |
| Current deferred revenue | - | 10.19M | 24.98M | 20.42M | 19.27M |
| Net debt | -610.58900M | -870.02700M | -481.46700M | -294.82900M | -394.34300M |
| Short term debt | 2.76M | 5.50M | 4.88M | 3.12M | 2.38M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 17.52M | 9.49M | 44.96M | 44.33M | 44.34M |
| Other stockholder equity | 1512.34M | 1472.84M | 883.45M | 601.11M | 567.64M |
| Property plant equipment | - | - | - | 32.77M | 17.79M |
| Total current assets | 628.11M | 928.61M | 561.87M | 369.38M | 458.56M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | 270.78M | 346.25M |
| Short term investments | - | - | - | - | - |
| Net receivables | 35.59M | 35.65M | 24.04M | 21.21M | 11.91M |
| Long term debt | - | - | 30.70M | 30.32M | 29.87M |
| Inventory | - | - | - | - | - |
| Accounts payable | 9.67M | 15.79M | 13.05M | 6.47M | 2.72M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -3.50500M | 0.12M | -1.30400M | 0.39M | -3.38800M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 89.43M | 10.53M | 5.25M | 8.46M | 3.45M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 89.49M | 28.26M | 33.48M | 41.23M | 21.24M |
| Capital lease obligations | 16.85M | 9.49M | 14.26M | 14.01M | 14.46M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -1.23500M | -4.32600M | -18.98700M | -2.03000M |
| Change to liabilities | - | - | - | 0.43M | 38.31M |
| Total cashflows from investing activities | -2.35000M | -1.23500M | -2.92900M | -18.98700M | -2.03000M |
| Net borrowings | -0.16800M | -31.90500M | 0.00000M | - | 15.00M |
| Total cash from financing activities | -0.13100M | 519.75M | 250.03M | 6.69M | 320.73M |
| Change to operating activities | - | - | - | 1.89M | -4.79100M |
| Net income | -218.96000M | -169.03100M | -180.66400M | -112.71700M | -66.81900M |
| Change in cash | -251.35200M | 353.10M | 187.82M | -99.52600M | 302.69M |
| Begin period cash flow | 879.52M | 526.97M | 339.15M | 438.68M | 135.99M |
| End period cash flow | 628.66M | 880.07M | 526.97M | 339.15M | 438.68M |
| Total cash from operating activities | -249.67500M | -164.72400M | -60.62800M | -86.11100M | -14.79400M |
| Issuance of capital stock | 0.00000M | 544.13M | 255.04M | 5.70M | 298.54M |
| Depreciation | 6.42M | 7.17M | 6.55M | 3.69M | 1.41M |
| Other cashflows from investing activities | 0.00549M | - | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | -2.77200M | - | -4.79100M |
| Change to account receivables | 2.90M | -11.95203M | -1.20200M | -1.64100M | 4.54M |
| Sale purchase of stock | - | - | - | - | - |
| Other cashflows from financing activities | -0.16809M | 7.53M | 0.68M | 0.99M | 22.18M |
| Change to netincome | - | - | - | 22.25M | 12.55M |
| Capital expenditures | 2.36M | 1.24M | 2.93M | 18.99M | 2.03M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -75.92802M | -33.46107M | 76.66M | 0.67M | 38.06M |
| Stock based compensation | 39.46M | 38.08M | 32.48M | 26.78M | 12.08M |
| Other non cash items | 45.21M | -2.26093M | 1.04M | 0.44M | 0.47M |
| Free cash flow | -252.61395M | -165.95900M | -63.55700M | -105.09800M | -16.82400M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BCYC Bicycle Therapeutics Ltd |
-0.1 2.33% | 4.20 | - | - | 5.07 | 0.61 | 21.22 | -2.1444 |
| NVO Novo Nordisk A/S |
-0.92 2.14% | 42.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-0.75 1.73% | 42.50 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
3.25 0.76% | 428.34 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
16.03 2.66% | 618.95 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Portway Building, Cambridge, United Kingdom, CB21 6GS
| Name | Title | Year Born |
|---|---|---|
| Dr. Kevin Lee M.B.A., Ph.D. | CEO & Exec. Director | 1969 |
| Mr. Lee H. Kalowski M.B.A., MBA | Pres & CFO | 1981 |
| Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE | Co-Founder, Non-Exec. Director & Member of Scientific Advisory Board | 1951 |
| Dr. Michael Skynner B.sc. Ph.d., Ph.D. | Chief Technology Officer | 1970 |
| Dr. Christian Heinis | Scientific Founder | NA |
| Mr. Alistair Milnes | Chief Operating Officer | NA |
| Dr. Nicholas Keen Ph.D. | Chief Scientific Officer | 1968 |
| Mr. David E. Borah CFA | VP of Capital Markets & Investor Relations | NA |
| Mr. Zafar Qadir | Gen. Counsel | NA |
| Dr. Gillian Langford | Head of Clinical and Project Management | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...